February 28, 2019
Amryt to enrol youngest patients to test potential EB treatment with market value more than €1 billion
Amryt Pharma can now enrol young Epidermolysis Bullosa (EB) patients between the ages of 21 days to 4 years old to test AP101 as a potential treatment.